Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
Browsing Tag: daily activity impairment
Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...